Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink

Kayla E. Hanson et al.

Are COVID-19vaccines associated with Guillain-Barré syndrome (GBS)?

In this cohort study of surveillance data from the Vaccine Safety Datalink that included 15.1 million doses of COVID-19 vaccines, the unadjusted incidence rate of confirmed GBS in the 1 to 21 days after receiving the Ad.26.COV2.S (Janssen) vaccine was 32.4 per 100 000 person-years, which was significantly higher than the background rate of GBS. The unadjusted incidence rate of confirmed GBS in the 1 to 21 days after mRNA vaccines was 1.3 per 100 000 person-years, which did not differ from the background rate.

These findings suggest an increased risk of GBS after Ad.26.COV2.S vaccination.

Latest articles

Mike McMorris and Chloe Neudorf The livestock sector in Ontario is a...
Ashley Turner An intact gut barrier is foundational for human health. The...
Dominique Richard Oligotherapy–Planetary–Metals uses small doses of individual trace minerals for therapeutic...
Gail Berger Adults having functional (symptoms without apparent cellular alterations) and organic...
Mike Stone Amazingly, it seems that this strive to be a better...
A Midwestern Doctor When you study the history of medicine, you will...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!